377 related articles for article (PubMed ID: 15078633)
1. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
3. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
4. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
5. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion: what is the evidence for its use?
Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BB
Ann Surg Oncol; 2004 Sep; 11(9):837-45. PubMed ID: 15313738
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
8. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion in regional melanoma.
Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB
Surg Oncol Clin N Am; 2006 Apr; 15(2):373-84. PubMed ID: 16632221
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
[TBL] [Abstract][Full Text] [Related]
12. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
13. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
14. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion.
Noorda EM; van Kreij RH; Vrouenraets BC; Nieweg OE; Muller M; Kroon BB; Aaronson NK
Eur J Surg Oncol; 2007 Aug; 33(6):776-82. PubMed ID: 17300914
[TBL] [Abstract][Full Text] [Related]
15. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; van Slooten GW; Nieweg OE
Surg Oncol Clin N Am; 2008 Oct; 17(4):785-94, viii-ix. PubMed ID: 18722918
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness.
van Akkooi AC; Golab-Schwarz HD; Eggermont AM; van Geel AN
Eur J Cardiothorac Surg; 2006 Aug; 30(2):408-10. PubMed ID: 16829108
[TBL] [Abstract][Full Text] [Related]
19. Prognostic scoring in patients with melanoma after adjuvant isolated limb perfusion.
Nagabhúshan JS; Murphy K; Angerson W; Kingsmore DB; Byrne DS; McKay AJ
J Surg Res; 2007 Mar; 138(1):22-4. PubMed ID: 17174339
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]